News

Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropr…

Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026 (CMS-4214-P) On Oct. 16, 2026, the Centers for

CMS Newsroom published a current U.S. medical or healthcare update on October 16, 2026. The story is receiving priority because the agent rated it as a timely, high-impact topic in drugs, treatments and FDA action. This article summarizes the verified source material and separates confirmed facts from issues that still need to be watched.

What happened?

Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026 (CMS-4214-P) On Oct. 16, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule to implement key sections of the Consolidated Appropriations Act of 2026 including section 6220 (Requiring Enhanced and Accurate Lists of (REAL) Health Providers Act) and section 6224 (Modernizing and Ensuring Pharmacy Benefit Manager Accountability).

Key facts from the source

  • 16, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule to implement key sections of the Consolidated Appropriations Act of 2026 including section 6220 (Requiring Enhanced and Accurate Lists of (REAL) Health Providers Act) and section 6224 (Modernizing and Ensuring Pharmacy Benefit Manager Accountability).
  • Modernizing and Ensuring Pharmacy Benefit Manager Accountability (Section 6224): CMS has several proposals to implement section 6224 of the CAA, which established requirements related to pharmacy benefit managers (PBMs) and their affiliates specific to the Medicare Part D program.
  • These proposals include new requirements governing the remuneration that PBMs and their affiliates may receive for services in connection with the utilization of Part D drugs, data reporting by PBMs to Part D prescription drug plan (PDP) sponsors and CMS, transparency in PBM price guarantee arrangements, disclosure by PBMs to PDP sponsors of the terms of certain agreements between PBMs or their affiliates and pharmaceutical manufacturers, and other requirements added by the CAA.
  • In this rule, we are proposing to implement the following sections: Adjustments to Medicare Part D Cost-Sharing Reductions for Low-Income Individuals (Section 6219): This proposed rule implements Section 6219 of the CAA that would reduce the generic drug copayment from $1 to $0 for full-benefit dual eligible individuals at or below 100% of the Federal Poverty Level, effective for plan years starting Jan.
  • Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026 (CMS-4214-P) On Oct.

Why this matters in U.S. healthcare

FDA actions involving drugs, biologics, therapies, or safety warnings can influence treatment options, prescribing information, access, monitoring, and manufacturer responsibilities.

Who may be affected?

Patients, prescribers, pharmacists, hospitals, health plans, manufacturers, and specialty practices may be affected depending on the product and indication.

What to watch next

  1. Read the FDA announcement and product labeling or safety communication.
  2. Watch for indication, eligibility, safety, supply, or access details.
  3. Look for payer and clinical-guideline updates after the federal action.
  4. Do not treat a news summary as prescribing guidance.

Key takeaway

This is a developing medical-news item selected for recency, U.S. relevance, potential impact, source quality, and independent coverage where available. The original source remains the authority for exact clinical, regulatory, safety, coverage, or policy details.

Frequently asked questions

Is this article medical advice?

No. It is a news summary based on cited public sources and is not a substitute for clinical guidance or patient-specific medical advice.

How current is this story?

The agent prioritizes articles published within its configured hot-news window and rejects older stories from automatic publication.

How is a topic selected?

Stories are ranked using freshness, U.S. relevance, potential healthcare impact, source authority, and corroboration across separate sources.


Sources

Primary source: Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026 (CMS-4214-P) — CMS Newsroom.

Continue from this guide

Medical Billing ServicesLearn more → Revenue Cycle ManagementLearn more → Medical Billing SolutionsLearn more →

Review your revenue cycle

Talk with Ultra Medical Solutions about billing, denials, A/R and workflow improvement opportunities.

Continue exploring

Resources

IDR Gateway Now Available

The new Independent Dispute Resolution (IDR) Gateway improves functionality, security, and efficiency of the Federal IDR process On November 13, 2026, the Dep

Read article →